Intellikine's Acquisition

Intellikine was acquired by Takeda Pharmaceutical on December 21, 2011.

Intellikine is developing small molecule therapies targeting the PI3K/mTOR pathway for treatment of cancer, inflammation and autoimmune diseases. In December 2011, Intellikine was acquired by Taked…

Articles about Intellikine's Acquisition: